EG-1-230   Click here for help

GtoPdb Ligand ID: 12733

Synonyms: compound 13 [PMID: 33479684]
Compound class: Synthetic organic
Comment: EG-1-230 is a high affinity, low potency μ opioid receptor (MOR) agonist [1,3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 3
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 43.7
Molecular weight 377.52
XLogP 3.31
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES C1=CC=C(C=C1)CCN2CC[C@@]3(CCC[C@H]2[C@@H]3/C=C/CO)C4=CC=CC(=C4)O
Isomeric SMILES OC/C=C/[C@H]1[C@H]2N(CC[C@@]1(CCC2)C=3C=C(C=CC3)O)CCC4=CC=CC=C4
InChI InChI=1S/C25H31NO2/c27-18-6-11-23-24-12-5-14-25(23,21-9-4-10-22(28)19-21)15-17-26(24)16-13-20-7-2-1-3-8-20/h1-4,6-11,19,23-24,27-28H,5,12-18H2/b11-6+/t23-,24-,25-/m0/s1
InChI Key FTDOOEOFAZGQEK-ZADLEFMZSA-N
References
1. Gutman ES, Bow E, Li F, Sulima A, Kaska S, Crowley R, Prisinzano TE, Lee YS, Hassan SA, Imler GH et al.. (2020)
G-Protein biased opioid agonists: 3-hydroxy-N-phenethyl-5-phenylmorphans with three-carbon chain substituents at C9.
RSC Med Chem, 11 (8): 896-904. [PMID:33479684]
2. Hiebel AC, Lee YS, Bilsky E, Giuvelis D, Deschamps JR, Parrish DA, Aceto MD, May EL, Harris LS, Coop A et al.. (2007)
Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an exceedingly potent antinociceptive in the enantiomeric C9-substituted 5-(3-hydroxyphenyl)-N-phenylethylmorphan series.
J Med Chem, 50 (16): 3765-76. [PMID:17625813]
3. Santos EJ, Nassehi N, Bow EW, Chambers DR, Gutman ES, Jacobson AE, Lutz JA, Marsh SA, Rice KC, Sulima A et al.. (2023)
Role of efficacy as a determinant of locomotor activation by mu-opioid receptor (MOR) ligands in female and male mice. II. Effects of novel MOR-selective phenylmorphans with high-to-low MOR efficacy.
Pharmacol Res Perspect, 11 (4): e01111. [PMID:37381112]